Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Cytokine Release Syndrome

• Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
• Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
• Anakinra in Dengue With Hyperinflammation ( AnaDen )
• Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
• Jafron Haemoadsorption During Cardiopulmonary Bypass
• Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
• High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
• PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
• Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
• Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
• Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
• Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
• Inflammatory Response to Opioid Versus Opioid Free Anesthesia
• The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters
• Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
• Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
• TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
• Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
• Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
• Anakinra in the Management of COVID-19 Infection
• Anakinra, COVID-19, Cytokine Storm
• Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
• Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
• Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
• Efficacy and Safety of Itolizumab in COVID-19 Complications
• To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients
• Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
• Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
• RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
• A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19
• Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
• Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
• CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
• Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
• Fluoxetine to Reduce Intubation and Death After COVID19 Infection
• Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
• Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
• Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
• Early Treatment of Cytokine Storm Syndrome in Covid-19
• Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
• Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
• Treatment of COVID-19 Patients With Anti-interleukin Drugs
• Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
• A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
• Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
• A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
• Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation
• Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
• Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)